MediBeacon Transdermal GFR Measurement System (GFR)
Medibeacon, Inc. · Decision date Nov 20, 2025
What did the FDA approve?
FDA records P230019/S003 as a supplement to PMA P230019, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Nov 20, 2025.
FDA approval order statement
approval for a manufacturing site located at Tjoapack, LLC, 341 JD Yarnell Industrial Parkway, Clinton, TN 37716 for labeling and secondary packaging of device.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Nov 20, 2025
- FDA change category
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P230019/S003
- Regulatory pathway
- PMA supplement
- Applicant
- Medibeacon, Inc.
- Product code
- SDK
- Decision code
- APPR
- Decision date
- Nov 20, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Transdermal test for Assessment of Glomerular Filtration Rate.
- Applicant
- Medibeacon, Inc.
- Product code
- SDK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230019. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230019 · Original PMA
MediBeacon Transdermal GFR Measurement System (TGFR)
P230019/S003 received
Application receipt date recorded by FDA.
P230019/S003 · FDA decision
Normal 180 Day Track No User Fee
P230019/S001 · Related supplement
MediBeacon Transdermal GFR Measurement System (TGFR)
P230019/S002 · Related supplement
MediBeacon Transdermal GFR Measurement System (TGFR)
P230019/S005 · Related supplement
MediBeacon Transdermal GFR System
Timeline entries are records held by MedtechLedger for P230019. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230019
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medibeacon, Inc. | PMA approval | Jan 17, 2025 | FDA | |
| Medibeacon, Inc. | PMA supplement | Dec 15, 2025 | FDA | |
| Medibeacon, Inc. | PMA supplement | Jun 10, 2026 | FDA | |
MediBeacon Transdermal GFR SystemP230019/S005 | Medibeacon, Inc. | PMA supplement | Oct 2, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medibeacon, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 425 N. New Ballas Rd., Suite 100, St. Louis, MO, 63141
Sources and methodology
- Original FDA record: P230019/S003
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


